In a report released Wednesday, analysts at Canaccord Genuity reiterated Stryker's stock "buy" rating.
Here are five things to know:
1. Canaccord Genuity presently has a target price of $108.00 on Stryker's stock, thus indicative of a potential upside of 13.56 percent from the Stryker's current price.
2. On Friday, May 22, Zacks' analysts upgraded Stryker stocks from a "hold" rating to a "buy" rating. The analysts set a $108.00 price target on the stock in a research note.
3. Stryker currently has an average rating of "buy" and a consensus target price of $99.47.
4. Ronda Stryker, director of the company, sold 12,000 shares this past Wednesday for a total transaction of $1,135,320.00. Each share sold at an average price of $94.61.
5. On Tuesday, April 21, Stryker announced its earnings, reporting $1.11 earnings per share for the quarter, surpassing the consensus estimate of $1.08 by $0.03.
For more news:
American Society of Regional Anesthesia and Acute Pain Medicine Meeting — 3 presentations to know
$55k is the average medical resident salary — 8 key statistics
7 statistics on the PPACA & physician practices